Skip to main content

Find Clinical Trials

Home
Conditions
Hepatitis B

Clinical trial condition

Hepatitis B

Explore clinical trials studying Hepatitis B. Study availability and eligibility vary by location and protocol.

725 public trials 59 recruiting studies

Refine in advanced search Browse all conditions

Hepatitis B trial results

Completed

A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.

NCT00291941

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: O.L.Vrouwziekenhuis Aalst Aalst, Belgium

RHMS La Madeleine ATH Ath, Belgium

RHMS Clinique Louis Caty Baudour Baudour, Belgium

AZ -VUB Dienst Nefrologie Brussels, Belgium

View all 24 locations

View Trial Details

Completed

Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule

NCT00480116

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: Vaccination and Travel Medicine Centre Poliklinika II Hradec Králové, Czechia

View Trial Details

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y

NCT00698906

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

NCT00699231

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Brussels, Belgium

View Trial Details

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

NCT00698555

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Ghent, Belgium

View Trial Details

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

NCT00697931

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Leuven, Belgium

View Trial Details

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

NCT00697775

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Mainz, Germany

View Trial Details

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

NCT00697840

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

NCT00697853

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trial Call Center Brussels, Belgium

View Trial Details

Completed

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

NCT00698087

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details